Heart disease remains the leading cause of death in the United States, with the American Heart Association reporting that cardiovascular disease accounted for more than 940,000 deaths in 2022. The problem is worsening: annual health care costs for cardiovascular conditions are forecast to increase from $393 billion in 2020 to $1.4 trillion by 2050. Into this persistent and costly healthcare burden steps Cardio Diagnostics Holdings (NASDAQ: CDIO), a Chicago-based precision cardiovascular medicine company that is applying artificial intelligence, epigenetics and genetics to a problem that traditional diagnostic tools have never fully solved: detecting coronary heart disease, including forms that standard methods routinely miss, from a simple blood draw.
What makes Cardio Diagnostics’ approach distinct is its ability to detect coronary heart disease earlier and with high sensitivity. The company’s recent commercial and regulatory milestones give additional shape to the investment thesis. The scale of the problem that Cardio Diagnostics is working to address is difficult to overstate. According to the AHA, cardiovascular disease remains the leading cause of death across men, women, and most racial and ethnic groups in the nation, with one person dying every 34 seconds from the disease.
The company’s technology leverages epigenetics—changes in gene expression that do not alter the DNA sequence—combined with AI algorithms to identify biomarkers indicative of coronary heart disease. This approach aims to catch the disease in its early stages, when interventions can be most effective, potentially reducing mortality and healthcare costs. Traditional diagnostic methods, such as stress tests or imaging, can miss certain forms of heart disease, leading to delayed treatment and poorer outcomes.
Cardio Diagnostics’ precision medicine platform could have significant implications for patients, healthcare providers, and the broader industry. For patients, earlier detection means the possibility of lifestyle changes or treatments before a heart attack or other major cardiac event occurs. For providers, the test offers a non-invasive, accessible option that could be integrated into routine check-ups, potentially improving diagnostic accuracy and patient management. For the healthcare system, reducing the burden of advanced heart disease could help curb the projected rise in costs.
The company’s progress is noteworthy, but investors should be aware of forward-looking statements and risks. As with any early-stage medical technology, there are uncertainties regarding regulatory approvals, market adoption, and competition. The full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer. The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.
Forward-looking statements in this article involve risks and uncertainties, including those set forth in the company's SEC filings. Undue reliance should not be placed on forward-looking statements, and the company undertakes no duty to update this information unless required by law.
